ALCAM and colorectal carcinoma: Only one study recorded that CD166 expression may be a predictive marker of clinical outcomes in stage II CRC patients with multivariate logistic regression analysis (OS: OR = 9.97, 95% CI = 1.17-84.90, P = 0.035; disease-specific survival: OR = 29.02, 95% CI = 2.17-389.08, P = 0.011) [23].